Jafron Biomedical Co Ltd Net Asset Quality Index
Jafron Biomedical Co Ltd net asset quality index. Jafron Biomedical Co Ltd (300529) has a Net Asset Quality Index of 66.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.20 Billion minus total liabilities of CN¥1.74 Billion yields net assets of CN¥3.46 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300529 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Jafron Biomedical Co Ltd (2011–2025)
Net asset quality index of Jafron Biomedical Co Ltd from 2011 to 2025. This chart shows how Jafron Biomedical Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 66.6%, representing net assets of CN¥3.46 Billion against total assets of CN¥5.20 Billion CNY. See Jafron Biomedical Co Ltd net assets for net asset value and shareholders' equity analysis.
Jafron Biomedical Co Ltd Net Asset Quality Index by Year (2011–2025)
Jafron Biomedical Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300529 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 64.2% | CN¥3.47 Billion | CN¥5.41 Billion | CN¥1.94 Billion | ▲ +2.2 pp |
| 2024 | 61.9% | CN¥3.33 Billion | CN¥5.38 Billion | CN¥2.05 Billion | ▲ +5.1 pp |
| 2023 | 56.9% | CN¥3.15 Billion | CN¥5.54 Billion | CN¥2.39 Billion | ▼ -9.4 pp |
| 2022 | 66.3% | CN¥3.59 Billion | CN¥5.41 Billion | CN¥1.82 Billion | ▼ -4.0 pp |
| 2021 | 70.3% | CN¥3.38 Billion | CN¥4.81 Billion | CN¥1.43 Billion | ▼ -17.7 pp |
| 2020 | 88.1% | CN¥2.83 Billion | CN¥3.22 Billion | CN¥383.06 Million | ▲ +1.1 pp |
| 2019 | 87.0% | CN¥2.17 Billion | CN¥2.49 Billion | CN¥324.13 Million | ▲ +3.1 pp |
| 2018 | 83.9% | CN¥1.72 Billion | CN¥2.05 Billion | CN¥330.04 Million | ▲ +2.2 pp |
| 2017 | 81.7% | CN¥1.39 Billion | CN¥1.70 Billion | CN¥310.90 Million | ▼ -9.4 pp |
| 2016 | 91.1% | CN¥1.18 Billion | CN¥1.30 Billion | CN¥115.81 Million | ▲ +9.2 pp |
| 2015 | 81.9% | CN¥564.06 Million | CN¥688.67 Million | CN¥124.61 Million | ▼ -2.0 pp |
| 2014 | 83.9% | CN¥452.42 Million | CN¥539.01 Million | CN¥86.59 Million | ▲ +1.6 pp |
| 2013 | 82.3% | CN¥380.12 Million | CN¥461.73 Million | CN¥81.60 Million | ▼ -2.8 pp |
| 2012 | 85.1% | CN¥290.84 Million | CN¥341.58 Million | CN¥50.74 Million | ▼ -2.4 pp |
| 2011 | 87.5% | CN¥215.57 Million | CN¥246.24 Million | CN¥30.68 Million | — |